Remdesivir was recently approved by the Food and Drug Administration for the treatment of hospitalized patients with coronavirus disease 2019 (COVID-19). It is the prodrug of an adenosine analogue that inhibits viral replication of several RNA virus families. In this review, we have explained the structure of the coronavirus. Further it showed promising results in terms of clinical improvement, shortening the recovery time, mortality rate, and the duration of oxygen need and several studies showed positive results of Remdesivir against the new variants. Here, we provide an overview of Remdesivir, mode of action, and the current studies exploring its clinical effectiveness.